tirzepatide free trial https://investor.lilly.com/news-releases/news-release-details/zepbound- tirzepatide-most-prescribed-weight-management “Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label FDA Approves Tirzepatide, A Potential

After 1 year of semaglutide treatment, in those with a history of metabolic surgery, %WL was significantly higher in patients who underwent RYGB (but not SG) compared with those with no MBS history

In the SURMOUNT-5 head-to-head trial, adults on Tirzepatide lost more weight than adults on semaglutide over 72 weeks about 20% versus 14% of body weight plus bigger reductions in waist size

Consistency matters more than acceleration

CrossRef Gut-liver metabolic and enterohormonal remodeling drives progression from metabolic dysfunction-associated steatotic liver disease to steatohepatitis Jaclyn A

Less potent than semaglutide/tirzepatide

Especially if we see high methane levels, we often do see some systemic chronic infection as well playing a role along the lines of Lyme disease, or one of the co infections for Lyme that we frequently see, especially with those methane-dominant SIBOs that dont respond very well or keep recurring